Invesco Russell 1000 Equal Weight ETF's Underlying Holdings Implies 11% Potential Gain.

The Invesco Russell 1000 Equal Weight ETF (EQAL) has an implied analyst target price of $57.94, indicating a 11.45% potential gain from its recent price of $51.99. Three of its underlying holdings with notable upside to their analyst target prices are Revolution Medicines Inc (RVMD), Ingram Micro Holding Corp (INGM), and Ashland Inc (ASH).

Title: Analysts Optimistic on Invesco Russell 1000 Equal Weight ETF and Its Holdings

The Invesco Russell 1000 Equal Weight ETF (EQAL) has garnered attention from analysts, with an implied target price of $57.94, indicating a potential 11.45% gain from its recent price of $51.99. Analysts have highlighted three of its underlying holdings—Revolution Medicines Inc (RVMD), Ingram Micro Holding Corp (INGM), and Ashland Inc (ASH)—as having notable upside to their analyst target prices.

# Invesco Russell 1000 Equal Weight ETF (EQAL)
The Invesco Russell 1000 Equal Weight ETF (EQAL) seeks to provide broad market exposure by investing in the Russell 1000 Index, which includes large-cap stocks. The ETF is designed to be equally weighted, meaning each stock has an equal representation in the portfolio. This strategy aims to mitigate the risk associated with sector concentration and provide a more diversified investment approach.

# Revolution Medicines Inc (RVMD)
Revolution Medicines Inc (RVMD) has received a Buy rating from Truist Securities with a price target of $99.00, indicating significant potential upside. The company's focus on targeting RAS mutations, which drive one-third of all new cancer diagnoses, positions it as a leader in the critical oncology segment. Analysts believe that the current share price does not fully reflect the "revolutionary potential" of the company's drugs, particularly its multi-target "pan" inhibitor, Daraxonrasib. The drug is projected to be an $8 billion-plus drug that will "accelerate faster than implied by consensus." Analysts expect this potential to gain appreciation in the next 12-18 months as new data emerges, supporting a bullish outlook on the stock [2].

# Ingram Micro Holding Corp (INGM)
Ingram Micro Holding Corp (INGM) has not received specific analyst ratings from the provided materials, but the company's position in the Invesco Russell 1000 Equal Weight ETF suggests that analysts consider it a strong holding. Ingram Micro is a leading global distributor of technology products and services, providing IT solutions to businesses and government agencies worldwide. The company's strong market position and diversified revenue streams make it an attractive holding for many investors.

# Ashland Inc (ASH)
Ashland Inc (ASH) has also been identified as a notable holding with potential for upside. Ashland is a global specialty chemical company that produces a wide range of products for various industries, including automotive, consumer products, and industrial markets. The company's diversified revenue streams and strong market position make it an attractive investment. While specific analyst ratings for Ashland were not provided in the source materials, its inclusion in the Invesco Russell 1000 Equal Weight ETF indicates that analysts view it favorably.

Conclusion
The Invesco Russell 1000 Equal Weight ETF (EQAL) offers a diversified investment approach with a focus on large-cap stocks. The ETF's underlying holdings, including Revolution Medicines Inc (RVMD), Ingram Micro Holding Corp (INGM), and Ashland Inc (ASH), have received positive analyst attention, with significant potential for upside. Investors should closely monitor the performance of these holdings and the overall market conditions to make informed investment decisions.

References
[1] https://www.marketbeat.com/instant-alerts/invesco-ltd-nyseivz-receives-consensus-recommendation-of-hold-from-analysts-2025-08-27/
[2] https://www.investing.com/news/analyst-ratings/revolution-medicines-stock-initiated-with-buy-rating-at-truist-securities-93CH-4226443